Abstract
Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
| Original language | English (US) |
|---|---|
| Journal | Seminars in Oncology |
| Volume | 32 |
| Issue number | SUPPL. 3 |
| DOIs | |
| State | Published - Apr 2005 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Southwest Oncology Group : Two decades of experience in non-small cell lung cancer. / Turrisi, Andrew T.; Crowley, John; Albain, Kathy; Gaspar, Laurie; Gandara, David R.
In: Seminars in Oncology, Vol. 32, No. SUPPL. 3, 04.2005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Southwest Oncology Group
T2 - Two decades of experience in non-small cell lung cancer
AU - Turrisi, Andrew T.
AU - Crowley, John
AU - Albain, Kathy
AU - Gaspar, Laurie
AU - Gandara, David R
PY - 2005/4
Y1 - 2005/4
N2 - Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
AB - Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
UR - http://www.scopus.com/inward/record.url?scp=18144410574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18144410574&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2005.03.022
DO - 10.1053/j.seminoncol.2005.03.022
M3 - Article
VL - 32
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - SUPPL. 3
ER -